• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Expert Rev Cardiovasc Ther . Cardiovascular outcomes of type 2 myocardial infarction among COVID-19 patients: a propensity matched national study

tetano

Editor, Senior Moderator
Expert Rev Cardiovasc Ther


. 2023 Apr 10.
doi: 10.1080/14779072.2023.2200933. Online ahead of print.
Cardiovascular outcomes of type 2 myocardial infarction among COVID-19 patients: a propensity matched national study


Yasar Sattar[SUP] 1 [/SUP], Amro Taha[SUP] 2 [/SUP], Neel Patel[SUP] 3 [/SUP], Varun Victor[SUP] 4 [/SUP], Anoop Titus[SUP] 5 [/SUP], Shazia Aziz[SUP] 6 [/SUP], Karthik Gonuguntla[SUP] 1 [/SUP], Harshith Thyagaturu[SUP] 1 [/SUP], Lalitsiri Atti[SUP] 7 [/SUP], Tarec Micho[SUP] 8 [/SUP], Talal Almas[SUP] 9 [/SUP], M Chadi Alraies[SUP] 10 [/SUP], Sudarshan Balla[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Myocardial infarction Type II (T2MI) is a prevalent cause of troponin elevation secondary to a variety of conditions causing stress/demand mismatch. The impact of T2MI on outcomes in patients hospitalized with COVID-19 is not well studied.
Methods: The Nationwide Inpatient Sample database from the year 2020 was queried to identify COVID-19 patients with T2MI during the index hospitalization. Clinical Modification (ICD-10-CM) codes "U07.1" and "I21.A1" were used as disease identifiers for COVID-19 and T2MI respectively. Multivariate adjusted Odds ratio (aOR) and propensity score matching (PSM) was done to compare outcomes among COVID patients with and without T2MI. The primary outcome was in-hospital mortality.
Results: A total of 1,678,995 COVID-19-weighted hospitalizations were identified in the year 2020, of which 41,755 (2.48%) patients had T2MI compared to 1,637,165 (97.5%) without T2MI. Patients with T2MI had higher adjusted odds of in-hospital mortality (aOR 1.44, PSM 32.27%, 95% CI 1.34-1.54) sudden cardiac arrest (aOR 1.29, PSM 6.6 %, 95% CI 1.17-1.43) and CS (aOR 2.16, PSM 2.73%, 95% CI 1.85-2.53) compared to patients without T2MI. The rate of coronary angiography (CA) in T2MI with COVID was 1.19 %, with significant use of CA among patients with T2MI complicated by CS compared to those without CS (4% vs 1.1%, p<0.001). Additionally, COVID-19 patients with T2MI had an increased prevalence of sepsis compared to COVID-19 without T2MI (48% vs 24.1%, p<0.001).
Conclusion: COVID-19 patients with T2MI had worse cardiovascular outcomes with significantly higher in-hospital mortality, SCA, and CS compared to those without T2MI. Long-term mortality and morbidity among COVID-19 patients who had T2MI will need to be clarified in future studies.

Keywords: COVID-19; Coronavirus; Myocardial infarction; SARS CoV2; Severe Acute Respiratory Syndrome Coronavirus 2; T2MI; Type two Myocardial Infarction.
 
Back
Top Bottom